HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Files An 8-K Regulation FD Disclosure

As previously announced, on March 23, 2017 HTG Molecular Diagnostics, Inc. (the “Company”) held a conference call to discuss the Company’s financial results for the fourth quarter and year ended December 31, 2016.   During the course of this call, the Company communicated, in response to a question regarding what levels of operating expenses should be expected in the first quarter of 2017 and other quarters in 2017, that the Company’s “cash burn was approximately $1.6 million in Q4.  And we see that pretty much at stable state right now.”  The Company wishes to clarify that the $1.6 million number was the average monthly net cash used during the fourth quarter of 2016 and that the “stable state” response related to operating expenses in the aggregate.  Cash and cash equivalents decreased by $4.8 million during the quarter, which was positively impacted by a $2.0 million investment in the Company.

About HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument. HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Recent Trading Information
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) closed its last trading session down -0.10 at 9.55 with 17,337,227 shares trading hands.